William Blair analyst John Sonnier said veno-occlusive disease, or VOD, is a well-known risk factor for AML patients who undergo transplant and he is optimistic of a timely resolution of the partial clinical hold placed on Seattle Genetics' early-stage trials of SGN-CD33A. He also noted that the Phase III CASCADE trial in elderly AML patients is ongoing and believes that trial will be registration-enabling and lead to FDA approval of the drug in 2019. Sonnier, who views today's selloff as overdone, recommends buying on weakness and keeps his Outperform rating on Seattle Genetics shares.